Collins R H
Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246.
Stem Cells. 1994 Nov;12(6):577-85. doi: 10.1002/stem.5530120605.
The CD34 antigen is expressed by early hematopoietic stem cells and progenitors and is detected on the surface of approximately 1% of bone marrow mononuclear cells [1-3]. Several monoclonal antibody-based methods have been developed to isolate these cells from clinical samples of bone marrow or peripheral blood based on their expression of this antigen, utilizing either biotin-avidin affinity, panning or immunomagnetic beads. Roughly 50% of CD34+ cells, with 20-90% purity, are recovered from clinical samples using these methods. Several clinical trials have demonstrated hematopoietic recovery using CD34+ selected cells to support high dose therapy. CD34+ cells may be useful in several areas of clinical stem cell transplantation, including purging of tumor cells, T cell depletion, stem cell expansion and gene therapy. This paper reviews the current methods for purification of CD34+ cells from clinical samples and discusses potential uses of these cells in transplantation.
CD34抗原由早期造血干细胞和祖细胞表达，约1%的骨髓单个核细胞表面可检测到该抗原[1-3]。基于该抗原的表达，已开发出几种基于单克隆抗体的方法，利用生物素-抗生物素蛋白亲和力、淘选或免疫磁珠从骨髓或外周血临床样本中分离这些细胞。使用这些方法从临床样本中回收的CD34+细胞纯度为20%-90%，回收率约为50%。多项临床试验已证明，使用CD34+选择细胞支持高剂量治疗可实现造血恢复。CD34+细胞可能在临床干细胞移植的多个领域有用，包括清除肿瘤细胞、T细胞清除、干细胞扩增和基因治疗。本文综述了从临床样本中纯化CD34+细胞的当前方法，并讨论了这些细胞在移植中的潜在用途。
